Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Gene therapy symbols : BLUE save search
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
Published: 2021-12-20 (Crawled : 13:30) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: -9.24%
H: 27.28%
C: 26.75%
clinical hold gene therapy cel therapy
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-11-22 (Crawled : 14:30) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 5.7%
H: 0.44%
C: -6.81%
fda blood transfusion application gene therapy therapy license cel
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-09-21 (Crawled : 01:00) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 0.0%
H: 1.56%
C: 0.11%
fda blood gene therapy therapy license gene therapies cel
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
Published: 2021-07-21 (Crawled : 11:00) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 0.7%
H: 1.6%
C: -0.11%
gene therapy therapy approval gene therapies
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer
Published: 2021-07-20 (Crawled : 11:00) - globenewswire.com
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: 0.07%
H: 3.43%
C: 3.22%
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: -0.53%
H: 3.74%
C: 3.13%
gene therapy therapy gene therapies
Global Gene Therapy Market Report 2021: Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
Published: 2021-07-13 (Crawled : 11:00) - prnewswire.com
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
|
| O: -0.64%
H: 1.28%
C: -1.0%
SRPT | $117.065 0.09% 0.09% 440K
|
Health Technology
|
| O: -0.88%
H: 1.98%
C: -1.13%
SGMO | News | $0.5212 2.18% 2.13% 2.3M
|
Health Technology
|
| O: -0.49%
H: 1.63%
C: 0.0%
RGNX | $15.885 1.57% 1.54% 360K
|
Health Technology
|
| O: -0.51%
H: 0.95%
C: -1.06%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 0.05%
H: 0.22%
C: -4.26%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -0.48%
H: 1.36%
C: -2.65%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.35%
H: 1.01%
C: 0.27%
EDIT | News | $5.465 -2.41% -2.47% 1.6M
|
Health Technology
|
| O: -0.15%
H: 1.2%
C: -4.78%
CRSP | News M | $56.46 1.44% 1.42% 1.2M
|
Health Technology
|
| O: -0.47%
H: 0.76%
C: -3.24%
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: -0.7%
H: 0.95%
C: -2.43%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: -2.09%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.56%
H: 1.51%
C: -0.23%
ADAP | $1.12 10.89% 9.82% 1.1M
|
Health Technology
|
| O: -0.25%
H: 0.25%
C: -1.78%
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: 2.11%
H: 0.0%
C: -4.83%
gene therapy therapy gene therapies
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
Published: 2021-07-09 (Crawled : 13:00) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 0.0%
H: 2.73%
C: 0.46%
gene therapy positive therapy gene therapies
Global Gene Therapy Market to Reach $2.7 Billion by 2026
Published: 2021-06-29 (Crawled : 14:15) - prnewswire.com
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
|
| O: 0.1%
H: 1.22%
C: -0.26%
SRPT | $117.065 0.09% 0.09% 440K
|
Health Technology
|
| O: 0.0%
H: 0.25%
C: -2.43%
SGMO | News | $0.5212 2.18% 2.13% 2.3M
|
Health Technology
|
| O: -0.91%
H: 1.08%
C: -2.66%
RGNX | $15.885 1.57% 1.54% 360K
|
Health Technology
|
| O: -0.26%
H: 1.59%
C: -1.13%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 1.13%
H: 0.1%
C: -8.26%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -2.19%
H: 17.95%
C: 16.17%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.04%
H: 0.53%
C: 0.38%
EDIT | News | $5.465 -2.41% -2.47% 1.6M
|
Health Technology
|
| O: 2.07%
H: 3.99%
C: 2.67%
CRSP | News M | $56.46 1.44% 1.42% 1.2M
|
Health Technology
|
| O: -0.41%
H: 1.48%
C: -0.34%
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: -0.26%
H: 0.64%
C: -3.25%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 1.49%
H: 0.0%
C: -2.44%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.42%
H: 0.15%
C: -0.62%
ADAP | $1.12 10.89% 9.82% 1.1M
|
Health Technology
|
| O: -0.68%
H: 1.6%
C: 0.23%
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: 0.0%
H: 0.59%
C: -2.96%
gene therapy therapy gene therapies market
Global Gene Therapy Markets Report 2021-2030: Antigen, Cytokine, Suicide Gene, Viral Vector, Non-Viral Vector, Oncological, Rare Diseases, Cardiovascular, Neurological Disorders, Infectious Diseases
Published: 2021-06-25 (Crawled : 11:00) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.16%
H: 0.09%
C: -0.13%
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
|
| O: 0.73%
H: 2.08%
C: 2.01%
SRPT | $117.065 0.09% 0.09% 440K
|
Health Technology
|
| O: 0.15%
H: 1.37%
C: 0.75%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
CLLS | News | $2.535 -3.98% -4.14% 47K
|
Health Technology
|
| O: -0.45%
H: 1.88%
C: 1.3%
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: -4.89%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: -1.97%
H: 0.24%
C: -2.72%
disease neurological cardiovascular infectious disease gene therapy therapy cardio gene therapies rare
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 1.06%
H: 0.35%
C: -0.44%
gene therapy therapy gene therapies cel
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
Published: 2021-05-21 (Crawled : 13:00) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 0.98%
H: 2.74%
C: 1.71%
gene therapy positive therapy gene therapies chmp
Cell and Gene Therapy Drug Delivery Devices Market, 2030 - Market Opportunities in the Strong Pipeline of Cell and Gene Therapies
Published: 2021-03-30 (Crawled : 22:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 0.11%
H: 0.77%
C: 0.22%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -1.55%
H: 0.51%
C: -0.22%
BDX | $234.36 0.21% 0.0% 800K
|
Health Technology
|
| O: -0.01%
H: 0.25%
C: -0.82%
VCEL | $46.38 2.2% 2.16% 360K
|
Health Technology
|
| O: 0.74%
H: 5.83%
C: 4.75%
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
|
| O: -0.81%
H: 4.45%
C: 2.03%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: -0.7%
H: 4.08%
C: 2.25%
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 0.66%
H: 5.38%
C: 4.65%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.21%
H: 0.29%
C: -0.17%
gene therapies gene therapy therapy drug device drug delivery liver
bluebird bio Presents Long-Term Data for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)
Published: 2021-03-15 (Crawled : 11:00) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 1.14%
H: 2.54%
C: 1.37%
gene therapy therapy gene therapies cel
bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program
Published: 2021-03-10 (Crawled : 12:39) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 14.21%
H: 0.55%
C: -5.33%
disease myeloid leukemia gene therapy therapy leukemia gene therapies acute myeloid leukemia aml
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.